The Manufacturers Life Insurance Company Makes New $1.07 Million Investment in Calumet, Inc. $CLMT

The Manufacturers Life Insurance Company acquired a new stake in Calumet, Inc. (NASDAQ:CLMT - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 29,852 shares of the oil and gas company's stock, valued at approximately $1,075,000.

Other hedge funds have also recently made changes to their positions in the company. Fifth Third Bancorp raised its holdings in shares of Calumet by 11.3% in the 2nd quarter. Fifth Third Bancorp now owns 3,407 shares of the oil and gas company's stock worth $123,000 after acquiring an additional 346 shares during the last quarter. Covestor Ltd lifted its position in Calumet by 29.1% in the 4th quarter. Covestor Ltd now owns 2,180 shares of the oil and gas company's stock valued at $43,000 after acquiring an additional 492 shares in the last quarter. Caldwell Sutter Capital Inc. boosted its stake in Calumet by 2.7% during the 2nd quarter. Caldwell Sutter Capital Inc. now owns 20,000 shares of the oil and gas company's stock valued at $720,000 after purchasing an additional 517 shares during the last quarter. ProShare Advisors LLC boosted its stake in Calumet by 6.9% during the 4th quarter. ProShare Advisors LLC now owns 12,613 shares of the oil and gas company's stock valued at $251,000 after purchasing an additional 817 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd increased its holdings in Calumet by 294.7% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 1,646 shares of the oil and gas company's stock worth $33,000 after purchasing an additional 1,229 shares in the last quarter. 34.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the company. TD Cowen increased their price objective on Calumet from $34.00 to $40.00 and gave the stock a "hold" rating in a research note on Wednesday, August 12th. HC Wainwright lifted their target price on Calumet from $60.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday. The Goldman Sachs Group upped their price target on Calumet from $40.00 to $45.00 and gave the stock a "neutral" rating in a report on Tuesday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Calumet in a research report on Friday, August 7th. Finally, UBS Group raised their price objective on Calumet from $26.00 to $47.00 and gave the company a "neutral" rating in a research note on Tuesday, August 25th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $51.75.

Calumet News Summary

Here are the key news stories impacting Calumet this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The firm increased its Q3 2026 EPS estimate to $0.62 from $0.60, Q4 to $0.24 from $0.22, FY2026 to $0.17 from $0.12, and FY2027 to $1.11 from $0.59. Its $75 price target implies substantial upside from the stock’s recent trading level. HC Wainwright earnings estimate report
• Positive Sentiment: The upward revisions suggest HC Wainwright expects stronger profitability over the next several quarters, potentially reflecting improved operating performance or business conditions. The revised FY2027 forecast is notably above the broader current-year consensus estimate of $0.46 per share. Calumet stock price expected to rise
• Neutral Sentiment: Calumet announced plans to attend the H.C. Wainwright conference. The event could provide investors with updates on strategy and operations, but no new financial information was disclosed in the announcement. Calumet conference announcement
• Neutral Sentiment: A Zacks analysis compared Calumet’s year-to-date performance with TXO Partners and the broader oil-and-energy sector. The article provides relative-performance context but does not indicate a new company-specific catalyst. Zacks Calumet sector performance analysis
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Calumet investors. Although the announcement does not establish wrongdoing, the prospect of litigation or regulatory concerns may weigh on sentiment and introduce uncertainty. Pomerantz investor investigation

Calumet Stock Performance

NASDAQ:CLMT opened at $53.13 on Friday. Calumet, Inc. has a 52 week low of $16.75 and a 52 week high of $54.69. The firm has a 50-day moving average price of $43.76 and a two-hundred day moving average price of $36.21. The firm has a market cap of $4.67 billion, a price-to-earnings ratio of -34.28 and a beta of 0.72.

Calumet (NASDAQ:CLMT - Get Free Report) last announced its earnings results on Friday, August 7th. The oil and gas company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($1.16). The firm had revenue of $1.45 billion during the quarter, compared to analysts' expectations of $1.12 billion. The firm's revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.70) EPS. As a group, sell-side analysts forecast that Calumet, Inc. will post 0.48 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Daniel Sajkowski sold 4,240 shares of Calumet stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $36.16, for a total transaction of $153,318.40. Following the sale, the director directly owned 77,718 shares in the company, valued at approximately $2,810,282.88. This trade represents a 5.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.15% of the company's stock.

About Calumet

Calumet Specialty Products Partners, L.P. NASDAQ: CLMT is an independent provider of high-value, essential product solutions derived from both petroleum and renewable feedstocks. The company operates an integrated network of manufacturing plants, blending terminals and storage facilities across North America, delivering customized products and technical services to industrial, automotive, consumer and agricultural end markets. By leveraging its scale and technical expertise, Calumet tailors supply chain and formulation solutions to meet stringent regulatory and performance requirements.

Calumet's product portfolio includes specialty lubricants and base oils for high-performance applications; process oils and waxes for food-grade, cosmetic and packaging uses; industrial solvents and cleaning solutions; and fuel additives designed to optimize engine performance and emissions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source